2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00094
    INO5042 14782-19-5 99.92%
    INO5042, a thiazole fused 1,4-naphthoquinone compound, and exhibits anti-inflammation activity.
    INO5042
  • HY-U00377
    Cathepsin Inhibitor 2 1017931-53-1 99.77%
    Cathepsin Inhibitor 2 is a potent Cathepsin S inhibitor extracted from patent WO2009123623A1, has a Ki of <20 nM.
    Cathepsin Inhibitor 2
  • HY-100754B
    (2R,5S)-Ritlecitinib 1792180-79-0 99.77%
    (2R,5S)-Ritlecitinib (2R,5S)-PF-06651600) is a JAK3 inhibitor (IC50=144.8 nM).
    (2R,5S)-Ritlecitinib
  • HY-100830A
    NCB-0970 2749881-54-5 98.81%
    NCB-0970 is the negative control of NCB-0846 (HY-100830). NCB-0846 is an orally active, selective inhibitor for Wnt, that inhibits Traf2- and Nck-interacting kinase (TNIK) with an IC50 of 21 nM. NCB-0846 blocks TGF-β signaling pathway by inhibiting SMAD2/3 phosphorylation and nuclear translocation.
    NCB-0970
  • HY-105037A
    Forigerimod TFA 99.88%
    Forigerimod TFA (IPP-201101 TFA) is a CD4 T-cell modulator. Forigerimod TFA is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod TFA can potently inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) .
    Forigerimod TFA
  • HY-106019C
    Liarozole dihydrochloride 1883548-96-6 ≥99.0%
    Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties.
    Liarozole dihydrochloride
  • HY-106765A
    Thymotrinan TFA 98.66%
    Thymotrinan (RGH-0205) TFA is a biologically active fragment of the naturally occurring thymus hormone thymopoietin and a immunomodulating peptide. Thymotrinan TFA exerts similar immunomodulatory activities to TP5 and to affect humoral as well as cellular responses.
    Thymotrinan TFA
  • HY-112433A
    (S)-NIK SMI1 2984765-48-0 99.28%
    (S)-NIK SMI1 is the isomer of NIK SMI1 (HY-112433), and can be used as an experimental control. NIK SMI1 is a potent, selective NF-κB inducing kinase (NIK) inhibitor, which inhibits NIK-catalyzed hydrolysis of ATP to ADP with IC50 of 0.23±0.17 nM.
    (S)-NIK SMI1
  • HY-113248S
    3-Nitro-L-tyrosine-d3 213386-10-8 99.9%
    3-Nitro-L-tyrosine-d3 is the deuterium labeled 3-Nitro-L-tyrosine (HY-113248). 3-Nitro-L-tyrosine serves as a biomarker of oxidative stress. 3-Nitro-L-tyrosine attenuates the pressor and vasoconstrictive effects of angiotensin II by inhibiting the α1-adrenergic receptor-mediated signaling pathway, and participates in hemodynamic regulation under pathological conditions such as inflammation and ischemia. 3-Nitro-L-tyrosine can be used in studies related to atherosclerosis, ischemia-reperfusion and sepsis.
    3-Nitro-L-tyrosine-d3
  • HY-113465S
    Leukotriene E4-d5 1240398-14-4 ≥98.0%
    Leukotriene E4-d5 is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
    Leukotriene E4-d5
  • HY-114175A
    Adenosine deaminase, Calf Spleen 9026-93-1
    Adenosine deaminase, Calf Spleen is an enzyme that catalyzes the irreversible deamination of adenosine and 2'-deoxyadenosine to inosine and 2'-deoxyinosine, respectively.
    Adenosine deaminase, Calf Spleen
  • HY-116100A
    HA155 1312201-00-5 98.50%
    HA-155 is a potent and selective autotaxin (ATX) inhibitor with an IC50 of 5.7 nM.
    HA155
  • HY-118828B
    12-Oxo phytodienoic acid (≥90%) 85551-10-6
    12-Oxo phytodienoic acid (≥90%) (12-OPDA (≥90%)) is a plant lipid-derived anti-inflammatory compound. 12-Oxo phytodienoic acid (≥90%) induces the expression of SOCS-1 and inhibits LPS (HY-D1056)-induced activation of the NF-κB and p38 MAPK signaling pathways. 12-Oxo phytodienoic acid (≥90%) inhibits LPS-induced expression of IL-6 and TNF-α, and reduces LPS-induced NO production by decreasing iNOS levels. 12-Oxo phytodienoic acid (≥90%) induces activation of the Nrf2 signaling cascade. 12-Oxo phytodienoic acid (≥90%) can be used for the research of neurodegenerative diseases.
    12-Oxo phytodienoic acid (≥90%)
  • HY-120268A
    SLM6031434 hydrochloride 1897379-34-8 99.1%
    SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD).
    SLM6031434 hydrochloride
  • HY-122058A
    KRH-3955 hydrochloride 2253744-59-9 98%
    KRH-3955 hydrochloride is an orally bioavailable CXCR4 antagonist. KRH-3955 hydrochloride inhibits SDF-1α binding to CXCR4 with an IC50 of 0.61 nM. KRH-3955 hydrochloride is also a highly potent and selective inhibitor of X4 HIV-1, with an EC50 of 0.3 to 1.0 nM.
    KRH-3955 hydrochloride
  • HY-126361A
    ZK824190 hydrochloride 2629177-12-2 99.42%
    ZK824190 hydrochloride is an orally available and selective urokinase plasminogen activator (uPA) inhibitor as a potential treatment for multiple sclerosis. IC50s of 237, 1600 and 1850 nM for uPA, tPA, and Plasmin, respectively.
    ZK824190 hydrochloride
  • HY-126752A
    Ophthalmic acid TFA 99.48%
    Ophthalmic acid TFA, an analogue of GSH, is a marker of oxidative stress and hepatic GSH consumption. Ophthalmic acid TFA is an inhibitor of Glyoxalase I reaction.
    Ophthalmic acid TFA
  • HY-130321S
    Lauroyl-L-carnitine-d3 chloride 2687960-76-3 99.95%
    Lauroyl-L-carnitine-d3 (chloride) is the deuterium labeled Lauroyl-L-carnitine chloride (HY-130321). Lauroyl-L-carnitine chloride is an orally active metabolite. Lauroyl-L-carnitine chloride significantly reverses the decrease in its target gene IL-10. Lauroyl-L-carnitine chloride alleviates Crohn' s-like colitis.
    Lauroyl-L-carnitine-d3 chloride
  • HY-131598C
    6-Thio-GTP tetrasodium 99.7%
    6-Thio-GTP (tetrasodium) is a Vav1-Rac inhibitor. 6-Thio-GTP (tetrasodium) inhibits TCR-stimulated T cell proliferation and CD28-mediated T cell survival. 6-Thio-GTP (tetrasodium) has an immunosuppressive effect in a mouse cardiac allograft transplant model and prolongs cardiac allograft survival.
    6-Thio-GTP tetrasodium
  • HY-132602A
    Remlarsen sodium 99.59%
    Remlarsen (MRG-201), a miR-29b mimic, acts a miR-29b agonist. Remlarsen sodium has the potential for preventiong formation of a fibrotic scar or cutaneous fibrosis.
    Remlarsen sodium
Cat. No. Product Name / Synonyms Application Reactivity